Form 4: Cue Biopharma Executive Lucinda Warren Granted Stock Options

Lucinda Warren, Chief Business Officer of Cue Biopharma, Inc., was granted stock options to purchase 250,000 shares of common stock on March 21, 2025.

Summary

• Lucinda Warren, the Chief Business Officer of Cue Biopharma, Inc., was granted stock options on March 21, 2025.
• The options allow her to purchase 250,000 shares of Cue Biopharma's common stock at an exercise price of $0.99 per share.
• The stock options vest in eight equal semi-annual installments, starting on September 21, 2025.
• The options expire on March 20, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it incentivizes management. The sentiment is moderately positive.

Positives

• The granting of stock options to a key executive like the Chief Business Officer can be seen as an incentive to align their interests with the long-term success of the company.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in biotech companies like Cue Biopharma.
• Comparable companies such as BioNTech, Moderna, and Gritstone Bio often use stock options as part of their executive compensation strategy.
• The vesting schedule of semi-annual installments over four years is also a typical arrangement.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Business Officer to drive company growth.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, Cue Biopharma, Lucinda Warren, Chief Business Officer, Form 4, executive compensation, equity